Incidence and severity of SARS-CoV-2 infection in lung transplant recipients in the Omicron era DOI Creative Commons
Neval Ete Wareham, Sebastian Rask Hamm,

Regitze Hertz Liebermann

et al.

JHLT Open, Journal Year: 2023, Volume and Issue: 1, P. 100004 - 100004

Published: Sept. 20, 2023

SARS-CoV-2 infection may cause serious illness in lung transplant recipients. We aimed to investigate incidence and severity of recipients the Omicron era. conducted a retrospective study investigating COVID-19 outcomes among between December 27, 2021 October 31st, 2022 Denmark. performed COX regression analysis potential risk factors with hospitalization as an endpoint. Among 236 included patients, 108 had first positive PCR during total 133 person-years follow-up, resulting rate 813 per 1000 (95% CI 670-977). The cumulative was 24.1% 26 – 32.1) admission intensive care unit 3.7% 0.1 6.3). 30-day mortality 0.9% 0 2.7). found that patients markedly higher, whereas lower omicron era compared earlier reports for delta On other hand, substantial proportion were hospitalized, suggesting continuous impact on this patient population.

Language: Английский

Shoulder Replacement in Patient Who Had a Heart and Lung Transplant DOI Creative Commons
Caroline R. Gross,

Zdravka Zafirova

Perioperative Medicine, Journal Year: 2025, Volume and Issue: unknown, P. 195 - 204

Published: Jan. 1, 2025

Language: Английский

Citations

0
Monoclonal Antibodies in Prevention and Early Treatment of COVID-19 in Lung Transplant Recipients: A Systematic Review and Perspective on the Role of Monoclonal Antibodies in the Future DOI Creative Commons

David A. Van Eijndhoven,

Robin Vos, Saskia Bos

et al.

Transplant International, Journal Year: 2025, Volume and Issue: 38

Published: Feb. 10, 2025

Coronavirus disease 2019 (COVID-19) has significantly impacted lung transplant recipients (LTR), who remain vulnerable to severe COVID-19 despite vaccination, prompting the use of monoclonal antibodies (mAbs) as a treatment option. This systematic review summarizes clinical efficacy mAbs against in adult LTR and provides perspective on role for infectious diseases future. A search PubMed/MEDLINE, Embase Cochrane was conducted studies reporting outcomes or solid organ (SOTR) including with drug-specific outcomes. Twelve were included. Pre-exposure prophylaxis reduced breakthrough infection LTR. Early correlated incidence outcomes, although statistical significance varied among studies. Overall, observational have demonstrated potential benefit LTR, both early treatment, well importance administration. Moreover, mAb therapy appeared safe could be viable option other pathogens, route that warrants further investigation. Systematic Review Registration https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=382133 , identifier CRD42022382133.

Language: Английский

Citations

0
Efficacy of sotrovimab on omicron BA.2, BA.4 and BA.5 subvariants of sars-cov-2 vs. other early therapies: a systematic review and meta-analysis of literature data DOI Creative Commons
Antonio Russo, Pierantonio Grimaldi, Mariantonietta Pisaturo

et al.

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: Jan. 30, 2024

Background The aim of this meta-analysis was to ascertain whether sotrovimab effective in reducing COVID-19 related hospitalization and mortality also Omicron BA.2, BA.4 BA.5 subvariants compared other antivirals index period. Methods A systematic review Randomized Controlled Trials (RCTs) observational studies comparing the efficacy early treatment with period, or monoclonal antibodies (mAbs), patients during BA.4, waves, conducted accordance PRISMA guidelines. We searched MEDLINE, Google Scholar Cochrane Library. Mortality were defined as outcomes. Results Four included, allowing a 8,041 patients. Meta-analysis showed no statistical difference between groups mortality. Precisely, RR group drugs (OR 0.38, 95% CI 0.10-1.49, p<0.166). As regards rate hospitalization, significant resulted treated those 1.66, 0.41-6.66, p=0.477). Interpretation In conclusion, evolution high risk progression, considering both

Language: Английский

Citations

2
Impact of COVID‐19 on long‐term lung function in lung transplant recipients: A single‐center retrospective cohort study DOI Creative Commons
Brice Touilloux, Matthaios Papadimitriou‐Olivgeris, Cédric Bongard

et al.

Transplant Infectious Disease, Journal Year: 2023, Volume and Issue: 25(5)

Published: Sept. 25, 2023

Available data are limited concerning long-term lung function (LF) evolution after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in transplant (LT) recipients. The aim of this study is to determine the effect first SARS-CoV-2 on LF LT We analyzed spirometry results recipients followed at our institution (March 2020 July 2022) 3, 6, and 12 months infection. Overall, 42 patients cohort (70%) with COVID-19 were included for analysis. Forced expiratory volume 1 s (FEV1 ) declined significantly 3 (-4.5%, -97 mL, 95% CI [-163; -31], p < .01), but not 6 (-3.9%, -65 [-168; +39], = .21). Results quite similar forced vital capacity. Spirometry values recipients, presented a mixed decline months, no significant months.

Language: Английский

Citations

3
Sotrovimab in solid organ transplant recipients with COVID-19: a systematic review and meta-analysis DOI Creative Commons
Behnam Amani, Rouhollah Shabestan, Kourosh Rajabkhah

et al.

Korean Journal of Transplantation, Journal Year: 2023, Volume and Issue: 37(4), P. 277 - 285

Published: Nov. 2, 2023

Background: Despite widespread implementation of vaccination against coronavirus disease 2019 (COVID-19), solid organ transplant recipients (SOTRs) can remain particularly vulnerable to this disease.The present study was conducted investigate the efficacy and safety sotrovimab in treatment SOTRs with COVID-19.Methods: A search performed PubMed, Cochrane Library, Web Science, medRxiv, Google Scholar gather relevant evidence through July 25, 2023.The quality included studies assessed using risk bias tool.Comprehensive Meta-Analysis software (ver.3.0, Biostat) employed for data analysis.Results: Ten studies, involving a total 1,569 patients, were included.The meta-analysis revealed significant differences between patients administered those treated standard care.These observed mortality rate (odds ratio [OR], 0.15; 95% confidence interval [CI], 0.03-0.67),hospitalization (OR, 0.35; CI, 0.21-0.57),intensive care unit (ICU) admission 0.16; 0.04-0.62), need supplemental oxygen therapy 0.22; 0.09-0.51),and mechanical ventilation 0.09; 0.01-0.70).However, no difference other treatments regarding rates hospitalization or ICU (P>0.05).Regarding safety, associated lower adverse events compared absence 0.02-0.86).Conclusions: These results suggest that may improve outcomes among COVID-19.Nevertheless, additional high-quality trials are necessary confirm these findings.

Language: Английский

Citations

2
Case Report: Kinetics and durability of humoral and cellular response of SARS-CoV-2 messenger RNA vaccine in a lung and kidney transplant recipient DOI Creative Commons
James P. Long, Mithil Soni, Pawel Muranski

et al.

Frontiers in Immunology, Journal Year: 2023, Volume and Issue: 14

Published: July 3, 2023

We present a case report of 63-year-old female health care worker who is 15 years status post double lung transplant and six living related donor kidney healthy on chronic immunosuppression regimen including prednisone, mycophenolate, tacrolimus received the SARS-CoV-2 mRNA vaccine (Pfizer-BioNTech BNT162b2) primary series had poor initial humoral response to COVID-19 vaccine, then demonstrated robust, sustained immune against S1 S2 antigens for over seven months after receiving recommended doses, booster dose, without developing or other serious adverse events. Her vaccination indicates effective formation anti-spike T cell memory despite immunosuppression. This provides comprehensive characterization her this series. As effectiveness data updated, as better understanding hybrid immunity emerges, these findings may reassure that recipients SOTs be capable durable responses emerging variants SARS-CoV-2.

Language: Английский

Citations

1
Incidence and severity of SARS-CoV-2 infection in lung transplant recipients in the Omicron era DOI Creative Commons
Neval Ete Wareham, Sebastian Rask Hamm,

Regitze Hertz Liebermann

et al.

JHLT Open, Journal Year: 2023, Volume and Issue: 1, P. 100004 - 100004

Published: Sept. 20, 2023

SARS-CoV-2 infection may cause serious illness in lung transplant recipients. We aimed to investigate incidence and severity of recipients the Omicron era. conducted a retrospective study investigating COVID-19 outcomes among between December 27, 2021 October 31st, 2022 Denmark. performed COX regression analysis potential risk factors with hospitalization as an endpoint. Among 236 included patients, 108 had first positive PCR during total 133 person-years follow-up, resulting rate 813 per 1000 (95% CI 670-977). The cumulative was 24.1% 26 – 32.1) admission intensive care unit 3.7% 0.1 6.3). 30-day mortality 0.9% 0 2.7). found that patients markedly higher, whereas lower omicron era compared earlier reports for delta On other hand, substantial proportion were hospitalized, suggesting continuous impact on this patient population.

Language: Английский

Citations

0